Oncology · small molecule, IV · clinical trial · GI toxicity in solid-tumour therapy
State of the asset · NBL-101
Synthetic demo data
KPIs for this asset
Configure| KPI | Now | 30 d ago | Target | Status |
|---|---|---|---|---|
| GI side effects (≥ 50) ↓ | 27% | 24% (+3) | 15% | 12 pp to go |
| Toxicity ≥ 50 ↓ | 15% | 11% (+4) | 10% | 5 pp to go |
| Strong responders ↑ | 28% | 28% (0) | 35% | 7 pp to go |
| At risk of discontinuation (≥ 60%) ↓ | 29% | 23% (+6) | 20% | 9 pp to go |
| Adherence ↑ | 76% | 79% (-3) | 80% | 4 pp to go |
Outcomes
Patients kept by an action
109 / €6.2M
churn at risk now: €9.9M · 4 with nothing proven yet
Side effects · largest unsolved
Poor sleep (quality < 40)
47% now · 38% with no proven action
Emerging patterns
5
EC-03 · High response / high intolerance
Strategy
Decision memos
where it works best, regimen, diagnostics, combinations
State of the program
Active patients
600
Strong responders
183 / 31%
At-risk patients
177
Intervention opportunities
71
match trajectories that benefited from GI-04
Predicted discontinuations / 30 d
128
Emerging clusters
3
C
LIFE OS copilot · OFF
Learning at scale is not being applied to patients. Turn on Assist or Auto.
Predicted vs observed
Baseline model expectation against what the trajectories actually did.
| Metric | Predicted | Observed |
|---|---|---|
| Response | 52% | 59% |
| Severe GI toxicity | 18% | 15% |
| Discontinuation | 24% | 21% |
| Treatment persistence | 66% | 70% |
LIFE OS learned this week
All insightsA new treatment-response phenotype emerged
184 patients demonstrate early response followed by tolerance deterioration. LIFE OS flags the pattern around day 24; clinical recognition has typically come at day 61.
71 patients could benefit from intervention
Their trajectories currently resemble previous GI-04 responders. Among comparable trajectories, GI-04 reduced symptom burden by 17% and 65% improved.
State S14 predicts discontinuation
Patients entering treatment in state S14 are 2.8× more likely to reach high discontinuation risk than the program average (160 patients).
Unexpected strong responders
32 patients previously classified as moderate responders now show sustained response despite an early toxicity episode.